Targeting this particular type of innate immune cells or interfering with ... macrophages restores tumor immunity and inhibits PDAC metastasis." Key contributor Professor Ainhoa Mielgo commented ...

By Dr. Sanchari Sinha Dutta, Ph.D. New research uncovers how distinct molecular profiles and immune signatures in metastatic pancreatic cancer impact survival and guide tailored treatment strategies.

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form ... and spread in pancreatic ductal adenocarcinomas (PDAC), the most common form of pancreatic cancer.

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

In a new study, researchers at the University of California San Diego School of Medicine have discovered that an enzyme called MICAL2 promotes tumor growth and spread in pancreatic ductal ...

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized ... Demographic, clinical, and histological data, including tumor nodule metastasis stage, tumor grade ...

Further analyses indicated that IL-1 blockade prevented the trafficking of inflammatory immune cells such as neutrophils to the tumor, which promoted cancer progression. Additionally, in a clinical ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

In the current study, scientists generate and analyze genomic, transcriptomic, and T-cell receptor sequencing data of metastatic PDAC patients to explore molecular and immune differences between ...